Learn more about TECENTRIQ®▼ (atezolizumab), a cancer immunotherapy treatment, by clicking on the respective indication of interest:

 

HCC

TNBC

Hepatocellular carcinoma1,2

Tecentriq®, in combination with Avastin® (bevacizumab), is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.

Non-small cell lung cancer (NSCLC):1-4

Tecentriq®, in combination with Avastin® (bevacizumab), paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC). In patients with EGFR mutant or ALK-positive NSCLC, Tecentriq®, in combination with Avastin® (bevacizumab), paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies.

Tecentriq® as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC after prior chemotherapy. Patients with EGFR mutant or ALK-positive NSCLC should also have received targeted therapies before receiving Tecentriq®.

Tecentriq®, in combination with nab-paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous NSCLC who do not have EGFR mutant or ALK-positive NSCLC. 

 

Small cell lung cancer (SCLC):1,2

Tecentriq®, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).

 

Triple-negative breast cancer (TNBC):3,4

Tecentriq® in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumours have PD-L1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.

 

Urothelial carcinoma (UC): 1-4

Tecentriq® as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma:

  • after prior platinum-containing chemotherapy, or
  • who are considered cisplatin ineligible, and whose tumours have a PD-L1 expression ≥ 5%

 

References:

  1. TECENTRIQ® Summary of Product Characteristics 1200mg vial. Available at:  https://www.medicines.org.uk/emc/product/8442/smpc
  2. TECENTRIQ® Summary of Product Characteristics 1200mg vial. (Northern Ireland) Available at:  https://www.medicines.org.uk/emc/product/12134/smpc
  3. TECENTRIQ® Summary of Product Characteristics 840mg vial. Available at:  https://www.medicines.org.uk/emc/product/10697/smpc
  4. TECENTRIQ® Summary of Product Characteristics 840mg vial (Northern Ireland). Available at: https://www.medicines.org.uk/emc/product/12133/smpc
 


M-GB-00003339
Date of preparation: April 2021